170P EO2401 microbiome derived therapeutic vaccine + nivolumab +/- bevacizumab, in neoadjuvant, adjuvant and non-surgery linked treatment of recurrent glioblastoma: Phase I-II EOGBM1-18/ROSALIE study

Autor: Wick, W., IdBaih, A., Vieito Villar, M., Tabatabai, G., Stradella, A., Ghiringhelli, F., Burger, M., Mildenberger, I., Herrlinger, U., Touat, M., Wen, P., Wick, A., Gouttefangeas, C., Maia, A., Bonny, C., Paillarse, J-M., Fagerberg, J., Reardon, D.A.
Zdroj: In Immuno-Oncology and Technology December 2022 16 Supplement 1
Databáze: ScienceDirect